Abstract
Background: Efficacy of melatonin in treating sleep disorders has been demonstrated in numerous studies. Being with short half-life, melatonin needs to be formulated in extended-release tablets to prevent the fast drop of its plasma concentration. However, an attempt to mimic melatonin natural plasma levels during night time is challenging.
Methods: In this work, Artificial Neural Networks (ANNs) were used to optimize melatonin release from hydrophilic polymer matrices. Twenty-seven different tablet formulations with different amounts of hydroxypropyl methylcellulose, xanthan gum and Carbopol®974P NF were prepared and subjected to drug release studies. Using dissolution test data as inputs for ANN designed by Visual Basic programming language, the ideal number of neurons in the hidden layer was determined trial and error methodology to guarantee the best performance of constructed ANN.
Results: Results showed that the ANN with nine neurons in the hidden layer had the best results. ANN was examined to check its predictability and then used to determine the best formula that can mimic the release of melatonin from a marketed brand using similarity fit factor.
Conclusion: This work shows the possibility of using ANN to optimize the composition of prolonged-release melatonin tablets having dissolution profile desired.
Keywords: ANN, drug delivery, hydrophilic polymers, melatonin, similarity fit factors, tablet formulation.
Current Drug Delivery
Title:Optimization of Melatonin Dissolution from Extended Release Matrices Using Artificial Neural Networking
Volume: 13 Issue: 4
Author(s): Martarelli D., Casettari L., Shalaby K.S., Soliman M.E., Cespi M., Bonacucina G., Fagioli L., Perinelli D.R., Lam J.K.W. and Palmieri G.F.
Affiliation:
Keywords: ANN, drug delivery, hydrophilic polymers, melatonin, similarity fit factors, tablet formulation.
Abstract: Background: Efficacy of melatonin in treating sleep disorders has been demonstrated in numerous studies. Being with short half-life, melatonin needs to be formulated in extended-release tablets to prevent the fast drop of its plasma concentration. However, an attempt to mimic melatonin natural plasma levels during night time is challenging.
Methods: In this work, Artificial Neural Networks (ANNs) were used to optimize melatonin release from hydrophilic polymer matrices. Twenty-seven different tablet formulations with different amounts of hydroxypropyl methylcellulose, xanthan gum and Carbopol®974P NF were prepared and subjected to drug release studies. Using dissolution test data as inputs for ANN designed by Visual Basic programming language, the ideal number of neurons in the hidden layer was determined trial and error methodology to guarantee the best performance of constructed ANN.
Results: Results showed that the ANN with nine neurons in the hidden layer had the best results. ANN was examined to check its predictability and then used to determine the best formula that can mimic the release of melatonin from a marketed brand using similarity fit factor.
Conclusion: This work shows the possibility of using ANN to optimize the composition of prolonged-release melatonin tablets having dissolution profile desired.
Export Options
About this article
Cite this article as:
D. Martarelli, L. Casettari, K.S. Shalaby, M.E. Soliman, M. Cespi, G. Bonacucina, L. Fagioli, D.R. Perinelli, J.K.W. Lam and G.F. Palmieri, Optimization of Melatonin Dissolution from Extended Release Matrices Using Artificial Neural Networking, Current Drug Delivery 2016; 13(4) . https://dx.doi.org/10.2174/1567201812666150608101528
DOI https://dx.doi.org/10.2174/1567201812666150608101528 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Fiber-Optic Technologies in Laser-Based Therapeutics: Threads for a Cure
Current Pharmaceutical Biotechnology An Effective Brain Imaging Biomarker for AD and aMCI: ALFF in Slow-5 Frequency Band
Current Alzheimer Research Effect of Prenatal and Early Postnatal Nutritional Supplementation with Long-Chain Polyunsaturated Fatty Acids (LCPUFA) on Neurodevelopmental Outcome in Term Infants
Current Nutrition & Food Science Dysfunction of Magnocellular/dorsal Processing Stream in Schizophrenia
Current Psychiatry Research and Reviews Drug Delivery to the Back of the Eye Following Topical Administration: An Update on Research and Patenting Activity
Recent Patents on Drug Delivery & Formulation Selected Recent Advances in the Synthesis of Bioactive Compounds Using Olefin Metathesis as a Key Step
Current Organic Chemistry Psychiatric Disorders Associated with FXTAS
Current Psychiatry Reviews Actions of Rho-Kinase Inhibitors in Cardiovascular Diseases
Current Enzyme Inhibition Recent Patents of Gene Sequences Relative to the Phosphatidylinositol 3-kinase / Akt Pathway and their Relevance to Drug Discovery
Recent Patents on DNA & Gene Sequences L-Dopa Prodrugs: An Overview of Trends for Improving Parkinsons Disease Treatment
Current Pharmaceutical Design Hypothesis-Driven Medication Discovery for the Treatment of Psychostimulant Addiction
Current Drug Abuse Reviews Cognitive Impairment and Dementia in Patients with Parkinson Disease
Current Topics in Medicinal Chemistry Pharmacological and Non-pharmacological Therapies of Cognitive Impairment in Multiple Sclerosis
Current Neuropharmacology PET/MR Tomographs: A Review with Technical, Radiochemical and Clinical Perspectives
Current Radiopharmaceuticals Involvement of Immune Response in the Pathogenesis of Amyotrophic Lateral Sclerosis: A Therapeutic Opportunity?
CNS & Neurological Disorders - Drug Targets Histone Acetylation as a Potential Therapeutic Target in Motor Neuron Degenerative Diseases
Current Pharmaceutical Design The Growth Hormone Secretagogue Receptor (Ghs-R)
Current Pharmaceutical Design Stat3 Orchestrates Tumor Development and Progression: The Achilles Heel of Head and Neck Cancers?
Current Cancer Drug Targets Functional Connectivity in a Rat Model of Alzheimer's Disease During a Working Memory Task
Current Alzheimer Research Aspects of the Stability and Bioavailability of Carbohydrates and Carbohydrate Derivatives
Mini-Reviews in Medicinal Chemistry